EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with…

By Samantha Cambier, R. Sylvester, L. Collette, P. Gontero, M. Brausi, G. van Andel, W. Kirkels, F. Silva, W. Oosterlinck, S. Prescott and 6 more. European Urology, 2016

618 citations recorded by the source corpus.

Subfields: Immunology, Surgery

View Paper: https://www.semanticscholar.org/paper/00c9844d6b5d45e6347f62553f7e56a3276939eb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. M. Burger
2. R. Sylvester
3. M. Rouprêt

In Surgery

1. M. Burger
2. M. Rouprêt
3. M. Babjuk
4. S. Shariat
5. R. Sylvester

Citations in the corpus

• European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). (2021, methodology): “In patients with intermediate- and highrisk tumours without CIS treated with 1–3 yr of maintenance BCG, EORTC risk groups and nomograms for BCGtreated patients were developed [74] (LE: 2a).”
• European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. (2019, methodology): “Using these data, the new EORTC risk groups and nomograms for BCG-treated patients were designed [65] (LE: 2a).”